RxDoctor Payments Data

Ismael Ortiz-Cartagena, MD

Interventional Cardiology · Bayamon, PRNPI 1083059547

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (59.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Edwards Lifesciences at 25.0% of the total.

$40,071in general payments, 2019–2025

Across 380 payments — averaging $105.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$10K
  • Boston Scientific$10K
  • Medtronic$9K
  • Abbott$7K
  • Johnson & Johnson$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$609
  • plus $2K from 14 others

What the payments were for

  • Consulting fees$1,9205%
  • Speaking & faculty fees$23,77059%
  • Travel & lodging$3,5289%
  • Food & beverage$10,55126%
  • Education$2271%
  • Gifts$750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,071 in reported general payments places this provider in the 75th percentile of 39 interventional cardiology providers in Puerto Rico.

See all interventional cardiology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$31,678
Medicare patients
69
Services billed
293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$103,352
XareltoRivaroxaban70$69,010
EntrestoSacubitril/Valsartan16$21,280
FarxigaDapagliflozin Propanediol31$19,401
BrilintaTicagrelor13$11,238
Candesartan Cilexetil69$9,313
Metoprolol Succinate202$4,942
Atorvastatin Calcium289$4,846
Rosuvastatin Calcium218$4,568
Ezetimibe128$3,733
Chlorthalidone170$3,726
Losartan Potassium246$3,651
Irbesartan82$3,596
Carvedilol183$2,732
Amlodipine Besylate315$2,591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$1,192$69,01070 claims
AstraZenecaFarxiga, Brilinta$445$30,63944 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 39 interventional cardiology providers in Puerto Rico.

Other interventional cardiology in Bayamon

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →